<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="217">
  <stage>Registered</stage>
  <submitdate>18/08/2005</submitdate>
  <approvaldate>23/08/2005</approvaldate>
  <actrnumber>ACTRN12605000204640</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of "Early Disease" in Familial Dilated Cardiomyopathy</studytitle>
    <scientifictitle>Evaluation of the efficacy of carvedilol to reduce echocardiographically-determined left ventricular dimensions in asymptomatic individuals with suspected early disease in familial dilated cardiomyopathy.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Familial dilated cardiomyopathy</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study involves a randomised, double-blind, placebo-controlled trial to determine whether oral administration of carvedilol over a 6-month period will reduce left ventricular dimensions in asymptomatic individuals who have a family history of dilated cardiomyopathy and echocardiographic changes that are suspected to represent early disease.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in left ventricular end-systolic and/or end-diastolic dimensions after 6 months of intervention when compared with baseline measurements.</outcome>
      <timepoint>At baseline and after 6 months of intervention.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical evidence of disease progression, with heart failure symptoms and/or worsening of left ventricular contractile function.</outcome>
      <timepoint>After 6 months of intervention when compared with baseline measurements.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Positive family history, absence of heart failure symptoms, increased left ventricular end-diastolic diameter (&gt;112% predicted) with or without mild impairment of systolic function (ejection fraction 40-55%).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Chronic airflow limitation with &gt;20% reversibility, heart rate less than 50 beats per minute, blood pressure &lt;80/50mmHg.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sequence randomised by Roche Pharmaceuticals who had nothing to do with administering the treatment. Pre-packaged drugs provided by Roche Pharmaceuticals</concealment>
    <sequence>SComputer software generated randomisation schedule with blocking</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/2003</anticipatedstartdate>
    <actualstartdate>10/07/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/05/2007</actualenddate>
    <samplesize>64</samplesize>
    <actualsamplesize>64</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital, Darlinghurst</primarysponsorname>
    <primarysponsoraddress>384 Victoria St Darlinghurst NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC Program Grant and institutional funds</fundingname>
      <fundingaddress>NHMRC
Level 1, 16 Marcus Clarke St, Canberra ACT 2601

Victor Chang Cardiac Research Institute
405 Victoria St Darlinghurst NSW 2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this study is to determine whether active treatment with carvedilol will improve short-term echocardiographic in asymptomatic individuals with familial dilated cardiomyopathy.</summary>
    <trialwebsite />
    <publication>Yeoh T, Hayward CS, Benson V, Sheu A, Richmond Z, Feneley MP, Keogh AM, Macdonald P, Fatkin D. A randomised, placebo-controlled trial of carvedilol in early familial dilated cardiomyopathy. Heart Lung Circulation 2011;20:566-573. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/07/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>A/Prof Diane Fatkin</name>
      <address>Victor Chang Cardiac Research Institute
384 Victoria St
Darlinghurst NSW 2010</address>
      <phone>+61 2 92958518</phone>
      <fax>+61 2 92958518</fax>
      <email>d.fatkin@victorchang.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>A/Prof Diane Fatkin</name>
      <address>Victor Chang Cardiac Research Institute
384 Victoria St
Darlinghurst NSW 2010</address>
      <phone>+61 2 92958518</phone>
      <fax>+61 2 92958518</fax>
      <email>d.fatkin@victorchang.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Diane Fatkin</name>
      <address>Victor Chang Cardiac Research Institute
405 Liverpool St Darlinghurst NSW 2010</address>
      <phone>+61 2 9295 8618</phone>
      <fax />
      <email>d.fatkin@victorchang.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>